NASDAQ:INCY Incyte (INCY) Stock Price, News & Analysis $60.43 +0.91 (+1.53%) Closing price 04:00 PM EasternExtended Trading$60.42 -0.01 (-0.02%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Incyte Stock (NASDAQ:INCY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Incyte alerts:Sign Up Key Stats Today's Range$58.04▼$60.7250-Day Range$55.17▼$74.4052-Week Range$50.35▼$83.95Volume2.93 million shsAverage Volume2.37 million shsMarket Capitalization$11.69 billionP/E Ratio223.82Dividend YieldN/APrice Target$74.69Consensus RatingHold Company OverviewIncyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.Read More… Incyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreINCY MarketRank™: Incyte scored higher than 94% of companies evaluated by MarketBeat, and ranked 21st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingIncyte has received a consensus rating of Hold. The company's average rating score is 2.21, and is based on 5 buy ratings, 13 hold ratings, and 1 sell rating.Amount of Analyst CoverageIncyte has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Incyte's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth34.57% Earnings GrowthEarnings for Incyte are expected to grow by 34.57% in the coming year, from $4.86 to $6.54 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Incyte is 223.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.91.Price to Earnings Ratio vs. SectorThe P/E ratio of Incyte is 223.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.43.Price to Earnings Growth RatioIncyte has a PEG Ratio of 0.41. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioIncyte has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Incyte's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.90% of the float of Incyte has been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Incyte has recently increased by 3.20%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIncyte does not currently pay a dividend.Dividend GrowthIncyte does not have a long track record of dividend growth. Sustainability and ESG3.1 / 5Environmental Score-2.83 Percentage of Shares Shorted3.90% of the float of Incyte has been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Incyte has recently increased by 3.20%, indicating that investor sentiment is decreasing. News and Social Media3.2 / 5News Sentiment0.72 News SentimentIncyte has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 38 news articles for Incyte this week, compared to 15 articles on an average week.Search Interest6 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows4 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,424,751.00 in company stock.Percentage Held by Insiders17.60% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Incyte's insider trading history. Receive INCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. Email Address INCY Stock News HeadlinesIncyte’s Promising Growth Potential and Strategic Positioning Amidst Market ChallengesApril 29 at 5:08 PM | tipranks.comIncyte (NASDAQ:INCY) Delivers Strong Q1 NumbersApril 29 at 4:06 PM | uk.finance.yahoo.comReal Americans Don’t Wait on Wall Street’s Next MoveWhat's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.April 29, 2025 | Premier Gold Co (Ad)Incyte expects minimal tariff hit, lifts blood cancer drug's 2025 forecastApril 29 at 4:06 PM | msn.comIncyte raises 2025 Jakafi revenue guidance to $3B amid strong Q1 growthApril 29 at 4:06 PM | msn.comIncyte Corporation (INCY) Q1 2025 Earnings Call TranscriptApril 29 at 1:18 PM | seekingalpha.comIncyte raises 2025 sales forecast for blood cancer drug after solid quarterApril 29 at 9:03 AM | reuters.comIncyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsApril 29 at 7:00 AM | businesswire.comSee More Headlines INCY Stock Analysis - Frequently Asked Questions How have INCY shares performed this year? Incyte's stock was trading at $69.07 on January 1st, 2025. Since then, INCY stock has decreased by 12.5% and is now trading at $60.43. View the best growth stocks for 2025 here. How were Incyte's earnings last quarter? Incyte Co. (NASDAQ:INCY) posted its quarterly earnings results on Tuesday, April, 29th. The biopharmaceutical company reported $1.16 EPS for the quarter, beating the consensus estimate of $1.01 by $0.15. The business's revenue was up 19.5% compared to the same quarter last year. Read the conference call transcript. Who are Incyte's major shareholders? Top institutional investors of Incyte include Robeco Institutional Asset Management B.V. (0.72%), Bank of New York Mellon Corp (0.63%), KBC Group NV (0.52%) and Sumitomo Mitsui Trust Group Inc. (0.24%). Insiders that own company stock include Maria E Pasquale, Steven H Stein, Jonathan Elliott Dickinson, Barry P Flannelly, Vijay K Iyengar, Sheila A Denton and Thomas Tray. View institutional ownership trends. How do I buy shares of Incyte? Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Incyte investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Today4/29/2025Last Earnings4/29/2025Next Earnings (Estimated)4/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBiotechnology Current SymbolNASDAQ:INCY CIK879169 Webwww.incyte.com Phone(302) 498-6700Fax302-425-2750Employees2,320Year Founded1991Price Target and Rating Average Stock Price Target$74.69 High Stock Price Target$92.00 Low Stock Price Target$52.00 Potential Upside/Downside+27.3%Consensus RatingHold Rating Score (0-4)2.21 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)$0.27 Trailing P/E Ratio220.45 Forward P/E Ratio12.07 P/E Growth0.41Net Income$32.62 million Net Margins0.77% Pretax Margin7.47% Return on Equity0.05% Return on Assets0.04% Debt Debt-to-Equity Ratio0.01 Current Ratio1.97 Quick Ratio1.94 Sales & Book Value Annual Sales$4.24 billion Price / Sales2.68 Cash Flow$0.46 per share Price / Cash Flow128.94 Book Value$17.82 per share Price / Book3.29Miscellaneous Outstanding Shares193,524,000Free Float159,464,000Market Cap$11.35 billion OptionableOptionable Beta0.89 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:INCY) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.